Clinical Trial

A Study of KM257 in Patients With Advanced HER2-positive or Expressing Solid Tumors.

Not Yet Recruiting Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated April 11, 2022 (before its estimated June 2024 completion). Its status may not reflect the trial's current state.
Summary
This is a first-in-human, 2-part study to investigate the safety, tolerability, pharmacokinetics and efficacy of KM257 by itself and combined with selected chemotherapy agents in patients with advanced HER2-positive or expressing cancers.
Trial Details
NCT Number NCT05320874
Lead Sponsor Xuanzhu Biopharmaceutical Co., Ltd.
Conditions Advanced Solid Tumor
Enrollment 232 participants
Start Date 2022-04
Primary Completion 2024-06 (estimated)
Study Completion 2026-11 (estimated)
Updated on ClinicalTrials.gov 2022-04-11